First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
Sarah P. Blagden(Churchill Hospital), Udai Banerji(Institute of Cancer Research), Jenny Prince(Chugai Pharma (United States)), Karen E. Swales(Institute of Cancer Research), Chara Stavraka(King's College London), Keith Jones(Chugai Pharma (United States)), Chris Twelves(University of Leeds), James Spicer(King's College London), Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), Shaun Decordova(Institute of Cancer Research), Rie Shiokawa(Chugai Pharma (United States)), Ruth Riisnaes(Institute of Cancer Research), Michiyasu Inatani(Chugai Pharma (United States)), Alan Anthoney(St James's University Hospital), Lorna Pope(Institute of Cancer Research), Andrea Zivi(Royal Marsden NHS Foundation Trust), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Kohei Noguchi(Chugai Pharma (United States)), Aurelius Olmin(Royal Marsden NHS Foundation Trust)
Cited by 47
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k